ADVICENNE (ALDVI.PA) Stock Price, Forecast & Analysis
EPA:ALDVI • FR0013296746
ALDVI.PA Key Statistics, Chart & Performance
The current stock price of ALDVI.PA is 2 EUR. In the past month the price increased by 15.74%. In the past year, price increased by 8.23%.
ALDVI.PA Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to ALDVI.PA. When comparing the yearly performance of all stocks, ALDVI.PA turns out to be only a medium performer in the overall market: it outperformed 62.04% of all stocks.
ALDVI.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ALDVI.PA. Both the profitability and financial health of ALDVI.PA have multiple concerns.
ALDVI.PA Financial Highlights
Over the last trailing twelve months ALDVI.PA reported a non-GAAP Earnings per Share(EPS) of -0.53. The EPS increased by 14.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -96.03% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ALDVI.PA Forecast & Estimates
9 analysts have analysed ALDVI.PA and the average price target is 4.08 EUR. This implies a price increase of 104% is expected in the next year compared to the current price of 2.
For the next year, analysts expect an EPS growth of 17.08% and a revenue growth 54.05% for ALDVI.PA
ALDVI.PA Ownership
ALDVI.PA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| SAN | SANOFI | 9.57 | 195.131B | ||
| SNW | SANOFI | 9.55 | 194.913B | ||
| 1SAN | SANOFI | 9.54 | 194.744B | ||
| 1MRK | MERCK KGAA | 14.92 | 55.76B | ||
| MRK | MERCK KGAA | 14.62 | 54.695B | ||
| UNC | UCB SA | 26.34 | 52.693B | ||
| UCB | UCB SA | 24.15 | 52.459B | ||
| 1BAYN | BAYER AG-REG | 8.75 | 41.984B | ||
| BAYN | BAYER AG-REG | 8.57 | 41.836B | ||
| IPN | IPSEN | 14.07 | 13.359B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About ALDVI.PA
Company Profile
Advicenne SA is a pharmaceutical company, which engages in the development of innovative treatments in Nephrology. The company is headquartered in Paris, Ile-De-France and currently employs 15 full-time employees. The company went IPO on 2017-12-06. The firm focuses on the development of paediatric friendly therapeutics for the treatment of orphan renal diseases and niche neurology indications. The Company’s medicines are developed for patients of all ages in the fields of nephrology and neurology. Its lead product includes ADV7103, which is in phase III, designed to address dRTA both in children for whom the disease is genetic as well as for adults who may have acquired the condition as a result of autoimmune disease. Apart from its lead product, the Company also develops a portfolio of products, including ADV6209, which is an oral liquid solution for moderate sedation; Likozam, which is designed to meet the unmet medical need of patients with partial and generalized chronic refractory epilepsy; Levidcen, which is used to address the unmet medical need of epileptic patients with partial onset seizures, and ADV7103 Cystinuria, among others.
Company Info
ADVICENNE
262, Rue du Faubourg Saint Honore
Paris ILE-DE-FRANCE FR
Employees: 13
Phone: 33185733620
ADVICENNE / ALDVI.PA FAQ
What does ADVICENNE do?
Advicenne SA is a pharmaceutical company, which engages in the development of innovative treatments in Nephrology. The company is headquartered in Paris, Ile-De-France and currently employs 15 full-time employees. The company went IPO on 2017-12-06. The firm focuses on the development of paediatric friendly therapeutics for the treatment of orphan renal diseases and niche neurology indications. The Company’s medicines are developed for patients of all ages in the fields of nephrology and neurology. Its lead product includes ADV7103, which is in phase III, designed to address dRTA both in children for whom the disease is genetic as well as for adults who may have acquired the condition as a result of autoimmune disease. Apart from its lead product, the Company also develops a portfolio of products, including ADV6209, which is an oral liquid solution for moderate sedation; Likozam, which is designed to meet the unmet medical need of patients with partial and generalized chronic refractory epilepsy; Levidcen, which is used to address the unmet medical need of epileptic patients with partial onset seizures, and ADV7103 Cystinuria, among others.
Can you provide the latest stock price for ADVICENNE?
The current stock price of ALDVI.PA is 2 EUR. The price decreased by -0.74% in the last trading session.
Does ADVICENNE pay dividends?
ALDVI.PA does not pay a dividend.
What is the ChartMill rating of ADVICENNE stock?
ALDVI.PA has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
When does ADVICENNE (ALDVI.PA) report earnings?
ADVICENNE (ALDVI.PA) will report earnings on 2026-03-26, after the market close.
What is the ownership structure of ADVICENNE (ALDVI.PA)?
You can find the ownership structure of ADVICENNE (ALDVI.PA) on the Ownership tab.